Quick Answer
Vicapsys Life Sciences, Inc. reported Cash and Equivalents of $9.4 thousand for fiscal year 2023.
Vicapsys Life Sciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $9.4K | -33.2% |
| 2022 | $14.1K | -93.5% |
| 2021 | $217.3K | +17023.3% |
| 2020 | $1.3K | -99.5% |
| 2019 | $264.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $89.6K | +67.3% | +850.6% |
| December 31, 2023 | $9.4K | -33.2% | -82.4% |
| September 30, 2023 | $53.5K | — | -76.9% |
| June 30, 2023 | $231.3K | — | +5486.4% |
| March 31, 2023 | $4.1K | -95.9% | -70.6% |
| December 31, 2022 | $14.1K | -93.5% | -86.1% |
| March 31, 2022 | $101.3K | +232.6% | -53.4% |
| December 31, 2021 | $217.3K | +17023.3% | +31.3% |
- Vicapsys Life Sciences, Inc. showed a decrease of -33.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2023 period, Vicapsys Life Sciences, Inc.’s cash and equivalents has declined by 96.4% (from $264.2 thousand to $9.4 thousand).
- The most recent figure is from Vicapsys Life Sciences, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on October 21, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: